The global medical community is currently engaged in a rigorous debate over the fundamental definition of obesity, a discussion that carries significant implications for millions of patients and the healthcare systems that serve them. At the center of this controversy is a recent critique published in The Journal of Clinical Endocrinology & Metabolism by the Endocrine Society. The organization has expressed profound concerns regarding a new obesity framework proposed by The Lancet Commission, arguing that the suggested shift in diagnostic criteria—from a Body Mass Index (BMI) focus to a requirement for proven organ dysfunction—could inadvertently complicate clinical workflows, delay life-saving treatments, and exacerbate existing health inequities.
As obesity rates continue to climb globally, the need for a precise and actionable medical definition has never been more urgent. However, the Endocrine Society warns that the Lancet Commission’s proposed framework introduces conceptual and practical hurdles that may hinder rather than help the management of this chronic disease. By requiring clinicians to definitively prove that excess body fat is the direct cause of measurable organ impairment before a formal diagnosis of "clinical obesity" can be made, the new framework risks creating a diagnostic bottleneck in an already strained healthcare environment.
The Evolution of Obesity Diagnosis and the Lancet Proposal
For decades, the primary tool for diagnosing obesity has been the Body Mass Index (BMI), a simple calculation of weight in kilograms divided by the square of height in meters. While BMI has long been criticized for its inability to distinguish between muscle mass and adipose tissue, its ease of use made it a universal standard for screening and population-level data collection. In recent years, however, there has been a push toward a more "pathophysiological" approach that looks at how fat affects health rather than just how much a person weighs.
The Lancet Commission’s proposed framework represents the most radical shift in this direction to date. The framework suggests a two-tiered classification: "clinical obesity," which requires evidence of organ dysfunction or health complications directly attributable to body fat, and "preclinical obesity," a category for individuals with elevated body fat who do not yet show signs of measurable medical impairment.
The Endocrine Society’s response, led by Ranganath Muniyappa, MD, PhD, of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), suggests that while the intention to modernize the definition is valid, the execution could be counterproductive. Dr. Muniyappa emphasizes that diagnostic definitions are not merely academic; they dictate who qualifies for surgery, who receives medication coverage, and how clinicians prioritize their daily patient loads.
Major Conceptual and Practical Challenges
The Endocrine Society’s critique focuses on three primary areas of concern that could negatively impact patient outcomes. The first is the complexity of proving causality. In clinical practice, it is often difficult to isolate excess body fat as the sole cause of a specific organ dysfunction. For example, a patient with hypertension or joint pain may have multiple contributing factors, including genetics, age, and lifestyle. Requiring a clinician to provide definitive proof that these issues are "caused" by obesity before a diagnosis is rendered could lead to diagnostic paralysis.
The second concern involves the "preclinical obesity" category. The authors argue that this label could be misinterpreted by insurers and health systems as a reason to deny early intervention. If a patient is classified as "preclinical," they may be excluded from receiving high-efficacy treatments, such as GLP-1 receptor agonists or bariatric surgery, until their condition worsens into "clinical obesity." This "wait-and-see" approach contradicts the modern medical shift toward preventive care and early intervention in chronic disease management.
Thirdly, the Endocrine Society highlights the issue of health equity. Implementing a framework that requires sophisticated testing to prove organ dysfunction—such as advanced imaging, metabolic testing, or specialist consultations—favors patients in high-resource urban medical centers. Patients in rural areas or those served by underfunded community clinics may lack access to the diagnostic tools necessary to meet the Lancet Commission’s criteria, further widening the gap in obesity care.
Supporting Data: The Rising Burden of Obesity
The urgency of this debate is underscored by the staggering statistics surrounding obesity. According to the World Health Organization (WHO), more than 1 billion people worldwide are now living with obesity. In the United States, the Centers for Disease Control and Prevention (CDC) reports that the adult obesity prevalence was 41.9% as of 2020, a significant increase from 30.5% in 2000.
The economic impact is equally severe. Annual medical costs for adults with obesity in the U.S. were estimated to be nearly $173 billion. Medical costs for adults with obesity were $1,861 higher than those for people with a healthy weight. These figures demonstrate that any change in how obesity is defined will have massive ripple effects across the global economy and insurance markets.
Furthermore, data from the National Health and Nutrition Examination Survey (NHANES) indicates that obesity-related complications, such as Type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), are appearing at younger ages. The Endocrine Society argues that the Lancet framework’s emphasis on "measurable health problems" might ignore the silent, long-term damage being done during the "preclinical" phase, missing a critical window for intervention.
Chronology of Obesity Framework Development
The current friction between the Endocrine Society and The Lancet Commission is the latest chapter in a decades-long evolution of obesity classification:
- 1997: The World Health Organization formally recognized obesity as a global epidemic and established the current BMI-based classification system (BMI ≥ 30 kg/m²).
- 2013: The American Medical Association (AMA) officially recognized obesity as a disease, a move intended to reduce stigma and encourage insurers to cover treatments.
- 2016: The American Association of Clinical Endocrinology (AACE) and the American College of Endocrinology (ACE) proposed a "complications-centric" model, which began the shift toward looking at obesity-related comorbidities.
- 2023-2024: The Lancet Commission on Obesity proposed its new framework, emphasizing organ dysfunction and the "preclinical" category.
- 2024: The Endocrine Society published its formal appraisal in The Journal of Clinical Endocrinology & Metabolism, warning of the risks associated with the Lancet proposal.
Reactions from the Medical and Academic Community
While the Endocrine Society has taken a firm stance, the broader medical community remains divided. Supporters of the Lancet framework argue that the current reliance on BMI is outdated and often leads to the over-medicalization of "healthy" individuals with high BMIs (such as athletes) while ignoring the risks of "normal-weight obesity" (individuals with low BMI but high visceral fat).
However, many frontline clinicians share the Endocrine Society’s pragmatism. Amy Rothberg, MD, of the University of Michigan and a co-author of the critique, argues for a more nuanced but accessible approach. "We need simpler ways to identify obesity earlier that don’t involve rigid diagnostic thresholds," Dr. Rothberg stated. She emphasizes that the focus should be on how much a treatment is likely to improve a patient’s daily life and long-term health, rather than on proving a single, exact cause of their condition.
Insurance experts have also weighed in, albeit more cautiously. If the Lancet framework were adopted, it would likely lead to a complete overhaul of ICD-10 (International Classification of Diseases) coding for obesity. This could provide insurers with a justification to restrict coverage for expensive new weight-loss medications, which currently cost upwards of $1,000 per month without insurance.
Broader Impact and Implications for Treatment Access
The most significant concern raised by the Endocrine Society is the potential for the new framework to act as a "barrier to care." In the current pharmaceutical landscape, the advent of highly effective anti-obesity medications (AOMs) has changed the prognosis for many patients. These drugs have shown the ability to reduce body weight by 15% to 22%, significantly lowering the risk of heart disease and diabetes.
If the Lancet framework requires a patient to already have organ damage before being eligible for "clinical obesity" status, they may be denied these medications during the stage when they would be most effective at preventing that very damage. This creates a medical paradox where a patient must become "sicker" to qualify for the medicine that would have kept them healthy.
Moreover, the "preclinical" label carries a psychological burden. It may lead to a lack of urgency in both the patient and the provider, delaying lifestyle interventions that are most successful when started early. The Endocrine Society proposes instead a "staging approach"—similar to the Edmonton Obesity Staging System (EOSS)—which considers metabolic, physical, and psychological factors without requiring the strict "proof of causality" demanded by the Lancet Commission.
Conclusion: Seeking a Practical Path Forward
The debate over the Lancet Obesity Framework highlights a fundamental tension in modern medicine: the desire for scientific precision versus the need for clinical utility. While The Lancet Commission seeks to ground the definition of obesity in rigorous pathophysiology, the Endocrine Society argues that such a definition must also be "practical for everyday clinical use."
The authors of the Endocrine Society communication, including experts from Stanford University, NYU Langone, and Cedars-Sinai, conclude that future frameworks should prioritize increasing access to care. They advocate for a definition that recognizes obesity as a complex, multi-factorial chronic disease but avoids creating new bureaucratic and diagnostic hurdles for patients and doctors.
As the medical community continues to refine its understanding of adiposity and health, the consensus remains that the ultimate goal must be the improvement of patient outcomes. Whether through BMI, staging systems, or organ-function assessments, the priority must be to ensure that the millions of individuals living with obesity can access safe, effective, and equitable treatment before the "preclinical" becomes the "irreversible."